Company Overview
Kiora Pharmaceuticals, Inc. operates as a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of therapies designed for the treatment of ophthalmic diseases. The company functions within the broader healthcare sector, specifically focusing on the biotechnology industry, which implies a reliance on research and development activities to bring novel drug candidates to market before generating significant commercial revenue. As of the latest available data, the company holds a market capitalization of $6.91M, while specific figures for annual revenue and employee count are not disclosed in the current financial snapshot. This limited market capitalization indicates that Kiora is a small-cap entity, suggesting it is in an early stage of its commercial lifecycle where the primary value driver is the potential success of its clinical pipeline rather than established sales volume.
Financial Health
The company reports a net income of $-10,835,154 and an EBITDA of $-9,434,446 for the trailing twelve months, while revenue data is unavailable. The substantial gap between the reported revenue figure of N/A and the negative net income reveals a cost structure heavily weighted toward research, development, and clinical trial expenses typical of clinical-stage biotechnology firms that have not yet achieved commercial product sales. Free cash flow stands at $-10,087,971, which indicates that the company is currently burning cash to fund its operations and clinical trials, thereby limiting its financial flexibility for external acquisitions or large-scale capital expenditures without raising additional capital. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the fact that the company has not yet generated positive revenue to calculate traditional profitability percentages. On the balance sheet, the company holds $17.09M in cash against $368,259 in debt, resulting in a debt-to-equity ratio of 2.28, which suggests a leveraged position relative to equity though the absolute debt load is low compared to cash reserves. The current ratio is 5.99, indicating a highly conservative stance on short-term liquidity where current assets significantly exceed current liabilities. Return on Equity is -51.7% and Return on Assets is -19.5%, metrics that reveal management is currently deploying capital to generate losses rather than profits, which is standard for clinical-stage development but signals that shareholder value is currently being consumed to advance the company's primary therapeutic assets.
Valuation Assessment
The trailing P/E ratio is N/A due to the absence of net income, while the forward P/E is listed as -0.84, implying that the market anticipates continued negative earnings or that valuation is being calculated on a pre-profitability basis. The price-to-book ratio is 0.44, which indicates that the company is trading at a discount to its book value, suggesting the market values the firm's tangible assets and intangible pipeline potential at less than the accounting book value. The price-to-sales ratio is N/A and the EV/EBITDA is 1.02, providing an alternative valuation metric that suggests the company is priced very cheaply relative to its enterprise value, though this metric is often less reliable for pre-revenue biotechnology companies with negative earnings. The stock has traded within a range defined by a 52-week high of $4.18 and a 52-week low of $1.76. Without a specific current price provided in the facts, the valuation context relies on this range to show the volatility and recent trading territory of the security. The beta value is N/A, meaning volatility data relative to the broader market is not available in the current dataset, preventing a direct comparison of price sensitivity to market movements.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet produced consistent revenue streams to calculate growth rates. Consequently, earnings are not growing faster or slower than revenue in a traditional sense because neither metric exists, implying that the company's growth is entirely dependent on the progression of its lead product, KIO-301, through Phase 2 clinical trials. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This approach indicates that the company reinvests all available resources, including its $17.09M cash reserve, back into research and development and clinical operations rather than paying dividends. The overall growth and income profile is characterized by a lack of current financial returns and dividends, with the entire investment thesis resting on the potential future commercialization of its ophthalmic disease therapies.